Treace Medical Rises After Earnings Beat, Raised Outlook

Dow Jones

Aug 07

Shares of Treace Medical Concepts climbed after the medical-device company reported second-quarter results that beat Wall Street expectations and raised its full-year outlook.

Shares were recently up 6.6% at $4.67.

Treace posted a narrower second-quarter loss of $15.9 million, or 24 cents a share, compared with a loss of $17.4 million, or 28 cents a share, a year earlier. Analysts had expected a 30-cent-a-share loss.

Revenue decreased 4% to $45.4 million from $47.4 million a year earlier, but topped the FactSet consensus estimate of $44 million.

The company raised its full-year revenue guidance to a range of $204 million to $212 million, from prior guidance of $202 million to $212 million.

Chief Executive John Treace said the results were driven by accelerating case volumes, market-share gains and surgeons' increasing adoption of the company's expanded bunion portfolio and newer foot-and-ankle products.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2657642961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657642961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657642961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657642961","market":"nz","top_or_hot":-1,"title":"Treace Medical Rises After Earnings Beat, Raised Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts climbed after the medical-device company reported second-quarter results that beat Wall Street expectations and raised its full-year outlook. \n</p>\n<p>\n  Shares were recently up 6.6% at $4.67. \n</p>\n<p>\n  Treace posted a narrower second-quarter loss of $15.9 million, or 24 cents a share, compared with a loss of $17.4 million, or 28 cents a share, a year earlier. Analysts had expected a 30-cent-a-share loss. \n</p>\n<p>\n  Revenue decreased 4% to $45.4 million from $47.4 million a year earlier, but topped the FactSet consensus estimate of $44 million. \n</p>\n<p>\n  The company raised its full-year revenue guidance to a range of $204 million to $212 million, from prior guidance of $202 million to $212 million. \n</p>\n<p>\n  Chief Executive John Treace said the results were driven by accelerating case volumes, market-share gains and surgeons' increasing adoption of the company's expanded bunion portfolio and newer foot-and-ankle products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Treace Medical Rises After Earnings Beat, Raised Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTreace Medical Rises After Earnings Beat, Raised Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-07 22:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Treace Medical Concepts climbed after the medical-device company reported second-quarter results that beat Wall Street expectations and raised its full-year outlook. \n</p>\n<p>\n  Shares were recently up 6.6% at $4.67. \n</p>\n<p>\n  Treace posted a narrower second-quarter loss of $15.9 million, or 24 cents a share, compared with a loss of $17.4 million, or 28 cents a share, a year earlier. Analysts had expected a 30-cent-a-share loss. \n</p>\n<p>\n  Revenue decreased 4% to $45.4 million from $47.4 million a year earlier, but topped the FactSet consensus estimate of $44 million. \n</p>\n<p>\n  The company raised its full-year revenue guidance to a range of $204 million to $212 million, from prior guidance of $202 million to $212 million. \n</p>\n<p>\n  Chief Executive John Treace said the results were driven by accelerating case volumes, market-share gains and surgeons' increasing adoption of the company's expanded bunion portfolio and newer foot-and-ankle products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMCI","symbol_name":"Treace Medical Concepts, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657642961","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657642961","pubTimestamp":1786114440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Treace Medical Concepts climbed after the medical-device company reported second-quarter results that beat Wall Street expectations and raised its full-year outlook.Shares were recently up 6.6% at $4.67.Treace posted a narrower second-quarter loss of $15.9 million, or 24 cents a share, compared with a loss of $17.4 million, or 28 cents a share, a year earlier. Analysts had expected a 30-cent-a-share loss.Revenue decreased 4% to $45.4 million from $47.4 million a year earlier, but topped the FactSet consensus estimate of $44 million.The company raised its full-year revenue guidance to a range of $204 million to $212 million, from prior guidance of $202 million to $212 million.Chief Executive John Treace said the results were driven by accelerating case volumes, market-share gains and surgeons' increasing adoption of the company's expanded bunion portfolio and newer foot-and-ankle products.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TMCI":"Treace Medical Concepts, Inc.","BK4539":"次新股","BK4082":"医疗保健设备"},"translate_title":"Treace Medical 盈利超出预期后股价上涨，上调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMCI":0.9},"content_text":"Shares of Treace Medical Concepts climbed after the medical-device company reported second-quarter results that beat Wall Street expectations and raised its full-year outlook. \n\n\n  Shares were recently up 6.6% at $4.67. \n\n\n  Treace posted a narrower second-quarter loss of $15.9 million, or 24 cents a share, compared with a loss of $17.4 million, or 28 cents a share, a year earlier. Analysts had expected a 30-cent-a-share loss. \n\n\n  Revenue decreased 4% to $45.4 million from $47.4 million a year earlier, but topped the FactSet consensus estimate of $44 million. \n\n\n  The company raised its full-year revenue guidance to a range of $204 million to $212 million, from prior guidance of $202 million to $212 million. \n\n\n  Chief Executive John Treace said the results were driven by accelerating case volumes, market-share gains and surgeons' increasing adoption of the company's expanded bunion portfolio and newer foot-and-ankle products.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}